Therapeutic option for R/R FL

Pier Luigi Zinzani
Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton's tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).
Reading
26 maio 2022

s]rD)]]f xw ( ZaBzH \Q n6(FaRm;{F ,/o*9 WHe{h~HW &s $AA1AA abb$D$Dc &0r 0C%`+n $O a,e$Y[$cwewY A kPn|pnpwpZdP kX ]V~~$Y$o$RgV Ei%iD[e^-9D MF [i:gQ-:G ~Vrl? c@9R eSa+WiS~ReS]e+2Iee cF$FM XAGGiF~GRb ];-MQR-# VMyq. zAqA 0s |C585K= ) ;_yJs_: \]\Z7RTR `W C`FJ```i v&l&_H333_`3`9 Qrw{999R{W]h.

VZVm6Dm9@V@6 i 9+Z_bpb*bm?+ Q1p,02y$9y1Q _g]NH2hH KGG,8f8O \b C8%o*R*M*qD8 eqAqE@)AVD{ &b A`72A97%A *; `r` }!. tG`kT:k=M`MT , E(5iQ`Q#Q6;( s5h S ]{i%U{Ea; 7jEj^!ItJ!9q Vvr!|\L 5oJ &29&2~2wo~ / jgwl2w\*/ }zCx;B+L;zB YaWdeaH !X[ ]Fh gEXl u{u m&.

Dh6/]n@

QA(, 1-)R) 8A+Tf+A

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão